Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 16.51% | Shs Outstand | 63.13M | Perf Week | -2.69% |
| Market Cap | 1.98B | Forward P/E | - | EPS next Y | -4.77 | Insider Trans | 4.30% | Shs Float | 14.80M | Perf Month | 18.79% |
| Enterprise Value | 1.62B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 82.23% | Perf Quarter | 45.73% |
| Income | -378.00M | P/S | 198.37 | EPS this Y | - | Inst Trans | - | Short Ratio | 16.78 | Perf Half Y | 73.11% |
| Sales | 10.00M | P/B | 5.90 | EPS next Y | 0.90% | ROA | -56.86% | Short Interest | 12.17M | Perf YTD | -13.47% |
| Book/sh | 5.32 | P/C | 2.77 | EPS next 5Y | - | ROE | -167.71% | 52W High | 44.60 -29.55% | Perf Year | 103.89% |
| Cash/sh | 11.36 | P/FCF | - | EPS past 3/5Y | - | ROIC | -61.53% | 52W Low | 13.50 132.74% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 6.23% 6.56% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 161.87 | EPS Y/Y TTM | -33.78% | Oper. Margin | 0.00% | ATR (14) | 1.90 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.94 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 60.10 | Recom | 2.20 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.94 | EPS Q/Q | -82.50% | SMA20 | 3.16% | Beta | 0.97 | Target Price | 22.00 |
| Payout | 0.00% | Debt/Eq | 0.33 | Sales Q/Q | -100.00% | SMA50 | 27.63% | Rel Volume | 0.48 | Prev Close | 31.13 |
| Employees | 167 | LT Debt/Eq | 0.33 | Earnings | Aug 11 | SMA200 | 21.86% | Avg Volume | 780.42K | Price | 31.42 |
| IPO Date | Sep 13, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.96% - | Net Debt/EBITDA | 0.36 | Volume | 378,123 | Change | 0.93% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-14-26 | Reiterated | Morgan Stanley | Equal Weight | $19 → $22 |
| Jan-06-26 | Reiterated | Jefferies | $52 → $48 | |
| Jan-06-26 | Downgrade | Morgan Stanley | Overweight → Equal Weight | $19 |
| Oct-28-25 | Reiterated | HC Wainwright & Co. | Buy | $44 |
| Oct-27-25 | Reiterated | Jefferies | $35 → $52 | |
| Oct-08-24 | Initiated | Jefferies | Buy | $35 |
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 10 | 5 | 50 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 139 | 0 | 62 | |
| Gross Profit | 10 | -134 | 50 | -62 | |
| Selling, General and Administrative Excl. Other | 53 | 30 | 17 | 14 | |
| Research and Development | 168 | 139 | 60 | 63 | |
| Other Operating Expense | 0 | -139 | 10 | -62 | |
| Operating Income | -211 | -164 | -37 | -76 | |
| Interest Expense | 7 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | -159 | 7 | 0 | -43 | |
| Net Income Before Taxes | -378 | -157 | -37 | -119 | |
| Income Taxes | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -378 | -157 | -37 | -119 | |
| Net Income From Continuing Operations | -378 | -157 | -37 | -119 | |
| Net Income | -378 | -157 | -37 | -119 | |
| EPS (Recurring) | -8.44 | -3.76 | -0.97 | -3.11 | |
| EPS (Basic, Before Extraordinaries) | -8.44 | -3.76 | -0.97 | -3.11 | |
| EPS (Diluted) | -8.44 | -3.76 | -0.97 | -3.11 | |
| EBITDA | -370 | -156 | -27 | -75 | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | 163.40 | 68.80 | — | — | |
| Gross Margin | 100.00 | -2,680.00 | 100.00 | — | |
| Operating Margin | -2,110.00 | -3,280.00 | -74.00 | — | |
| Net Margin | -3,780.00 | -3,140.00 | -74.00 | — | |
| Shares Outstanding | 45 | 42 | 38 | 38 | |
| Market Capitalization | 1,634 | 344 | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer | May 18 '26 | Buy | 16.88 | 60,000 | 1,012,800 | 96,928 | May 18 |
| MOULDER LEON O JR | Chief Executive Officer | Apr 29 '26 | Buy | 17.62 | 35,000 | 616,700 | 1,786,039 | Apr 29 |
| MOULDER LEON O JR | Chief Executive Officer | Apr 28 '26 | Buy | 18.02 | 25,000 | 450,500 | 1,751,039 | Apr 29 |
| Lu Hongbo | Director | Mar 31 '26 | Buy | 19.93 | 78,768 | 1,570,198 | 426,736 | Apr 02 |
| Fairmount Funds Management LLC | Director | Mar 31 '26 | Buy | 20.00 | 150,000 | 3,000,000 | 2,359,025 | Apr 01 |
| MOULDER LEON O JR | Chief Executive Officer | Mar 31 '26 | Buy | 19.31 | 34,000 | 656,540 | 1,726,039 | Mar 31 |
| MOULDER LEON O JR | Chief Executive Officer | Mar 30 '26 | Buy | 18.23 | 20,000 | 364,600 | 1,692,039 | Mar 31 |
| Allen Patricia L | Director | Feb 13 '26 | Buy | 26.36 | 4,160 | 109,658 | 19,860 | Feb 13 |
| Allen Patricia L | Director | Feb 12 '26 | Buy | 24.85 | 15,700 | 390,088 | 15,700 | Feb 13 |
| Lu Hongbo | Director | Feb 11 '26 | Buy | 22.50 | 25,985 | 584,663 | 347,968 | Feb 13 |
| MOULDER LEON O JR | Chief Executive Officer | Feb 02 '26 | Buy | 17.96 | 57,000 | 1,023,720 | 423,155 | Feb 03 |
| MOULDER LEON O JR | Chief Executive Officer | Jan 09 '26 | Buy | 16.55 | 20,000 | 331,000 | 366,155 | Jan 09 |
| MOULDER LEON O JR | Chief Executive Officer | Jan 08 '26 | Buy | 16.30 | 30,000 | 489,000 | 346,155 | Jan 09 |
| MOULDER LEON O JR | Chief Executive Officer | Jan 07 '26 | Buy | 16.38 | 50,000 | 819,000 | 316,155 | Jan 09 |
| Nunn Jason Raleigh | Director | Oct 09 '25 | Buy | 19.00 | 63,158 | 1,200,002 | 1,173,395 | Oct 14 |